Compare Elevance Health Inc. Common Stock (ELV) vs Toro Company (The) Common Stock (TTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Elevance Health Inc. Common Stock vs Toro Company (The) Common Stock — how do they compare? Elevance Health Inc. Common Stock trades at $429.83 (market cap $92.23B), while Toro Company (The) Common Stock trades at $98.27 (market cap $9.27B). The key difference: Elevance Health Inc. Common Stock is far larger — about 9.9× Toro Company (The) Common Stock's market cap, and Elevance Health Inc. Common Stock pays the higher dividend (1.62%). Which is the better fit depends on your goals — on Pluang, investors hold Elevance Health Inc. Common Stock for 1 Days and Toro Company (The) Common Stock for 0 Days on average.
| ELV | TTC | |
|---|---|---|
Market Cap | $92.23B | $9.27B |
Volume | 1,842,737 | 688,325 |
Sector | Health | Industrials |
52-Week High | $428.09 | $101.76 |
52-Week Low | $280.74 | $67.99 |
Typical Hold Time | 1 Days | 0 Days |
Enterprise Value | $113.04B | $10.17B |
Dividend Yield | 1.62% | 1.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Elevance Health (ELV) trades at $425.27, up 0.75% with a bullish technical outlook and strong institutional support. The stock shows consistent earnings beats with Q1 2026 EPS of $12.58 beating expectations by 16%, while maintaining solid fundamentals with $199.13B revenue and 11.2% ROE. Recent Medicare Advantage plan announcements and positive analyst coverage reinforce growth prospects.
ELV presents a compelling investment case with 71% analyst buy ratings and $445.13 price target offering 4.7% upside. However, declining 2026 profit margins to 2.46% and regulatory uncertainty in healthcare sector pose risks. The stock's current valuation at 18.81 P/E appears reasonable given earnings momentum and market position.
Toro Company (TTC) trades at $97.88, up 1.27% with strong technical momentum above its 50-day moving average. The company demonstrates solid fundamentals with consistent earnings beats, including Q2 2026 EPS of $1.33 beating expectations of $1.31, and raised full-year guidance. Revenue growth of 8.4% in Q3 2026 to $1.23 billion reflects robust demand across professional and residential segments, supported by infrastructure and automation initiatives under new CEO leadership.
Toro presents a balanced investment case with 36% analyst buy ratings and $117.50 price target suggesting 20% upside. However, execution risks from inflation, tariffs, and competitive pressures warrant caution. The stock's premium valuation (P/E 26.17) requires sustained earnings growth, making Q3 2026 results critical for validating current momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Elevance Health Inc. Common Stock
Elevance Health provides health plans and healthcare services. Its offerings include medical, behavioral health, pharmacy, dental, vision, and complex-care solutions, including through the Carelon business.
Read more on ELV →About Toro Company (The) Common Stock
The Toro Company designs, manufactures, and markets equipment for turf maintenance, snow and ice management, landscaping, construction, and irrigation. Its products serve golf courses, sports fields, and residential and commercial properties in more than 125 countries.
Read more on TTC →
